ArQule (ARQL) Misses Q1 EPS by 1c, Revenues Miss; Affirms 2Q EPS/Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. BIIB
7. CMG
8. TENB
9. KLAC
10. ETSY

Go back to ArQule (ARQL) Misses Q1 EPS by 1c, Revenues Miss; Affirms 2Q EPS/Revenue Outlook

ArQule (ARQL) PT Raised to $9 at Needham & Company

May 1, 2019 11:28 AM EDT

Needham & Company analyst Chad Messer raised the price target on ArQule (NASDAQ: ARQL) to $9.00 (from $7.00) while maintaining a Buy rating.

The analyst commented, :ArQule is currently enrolling a 75 mg dose cohort (cohort 8) in the Phase I study of ARQ531. A... More

ArQule (ARQL) PT Raised to $10 at Roth Capital

April 29, 2019 7:51 AM EDT

Roth Capital analyst Jotin Marango raised the price target on ArQule (NASDAQ: ARQL) to $10.00 (from $8.00) while maintaining a Buy rating.

The analyst comments "This spring, we are increasingly bullish on ArQule, following the material advance of the underappeciated Proteus/PROS program in... More